Ignite Creation Date:
2025-12-24 @ 7:52 PM
Ignite Modification Date:
2025-12-29 @ 12:37 PM
Study NCT ID:
NCT06220604
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-12-08
First Post:
2024-01-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'C000628674', 'term': 'deucravacitinib'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 731}}, 'statusModule': {'overallStatus': 'ACTIVE_NOT_RECRUITING', 'startDateStruct': {'date': '2024-03-09', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-12', 'dispFirstSubmitDate': '2025-11-13', 'completionDateStruct': {'date': '2027-09-20', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-12-04', 'studyFirstSubmitDate': '2024-01-15', 'studyFirstSubmitQcDate': '2024-01-15', 'dispFirstPostDateStruct': {'date': '2025-11-07', 'type': 'ESTIMATED'}, 'lastUpdatePostDateStruct': {'date': '2025-12-08', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2024-01-24', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2024-11-15', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': "JNJ-77242113 and Placebo Group: Percentage of Participants Achieving an Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater Than or Equal to (>=) 2 Grade Improvement From Baseline at Week 16", 'timeFrame': 'Baseline and Week 16', 'description': "Percentage of participants achieving an IGA score of 0 or 1 and \\>=2 grade improvement from baseline at Week 16 will be reported. The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4)."}, {'measure': 'JNJ-77242113 and Placebo Group: Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 90 Response at Week 16', 'timeFrame': 'Baseline and Week 16', 'description': 'Percentage of participants achieving PASI 90 response (\\>=90% improvement in PASI from baseline) at Week 16 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.'}], 'secondaryOutcomes': [{'measure': 'JNJ-77242113 and Placebo Group: Percentage of Participants Achieving an IGA Score of 0 at Week 16', 'timeFrame': 'Week 16', 'description': "Percentage of participants achieving an IGA Score of 0 at Week 16 will be reported. The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4)"}, {'measure': 'JNJ-77242113 and Placebo Group: Percentage of Participants Achieving PASI 75 Response at Weeks 4 and 16', 'timeFrame': 'Baseline, Weeks 4 and 16', 'description': 'Percentage of participants achieving PASI 75 response (\\>=75% improvement in PASI from baseline) at Weeks 4 and 16 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.'}, {'measure': 'JNJ-77242113 and Placebo Group: Percentage of Participants Achieving PASI 90 Response at Week 8', 'timeFrame': 'Baseline and Week 8', 'description': 'Percentage of participants achieving PASI 90 response (\\>=90% improvement in PASI from baseline) at Week 8 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.'}, {'measure': 'JNJ-77242113 and Placebo Group: Percentage of Participants Achieving PASI 100 Response at Week 16', 'timeFrame': 'Baseline and Week 16', 'description': 'Percentage of participants achieving PASI 100 response (100% improvement in PASI from baseline) at Week 16 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.'}, {'measure': 'JNJ-77242113 and Placebo Group: Percentage of Participants Achieving Scalp-specific Investigator Global Assessment (ss-IGA) Score of 0 or 1 and a >=2-grade Improvement From Baseline at Week 16', 'timeFrame': 'Baseline and Week 16', 'description': 'Percentage of participants achieving ss-IGA score of 0 or 1 and a \\>=2-grade improvement from baseline at Week 16 will be reported. The ss-IGA instrument is used to evaluate the disease severity of scalp psoriasis. The lesions are assessed in terms of the clinical signs of redness, thickness, and scaliness which are scored as: absence of disease (0), very mild disease (1), mild disease (2), moderate disease (3), and severe disease (4).'}, {'measure': 'JNJ-77242113 and Placebo Group: Percentage of Participants Achieving Psoriasis Symptom and Sign Diary (PSSD) Symptoms Score of 0 at Weeks 8 and 16', 'timeFrame': 'Weeks 8 and 16', 'description': 'Percentage of participants achieving PSSD symptoms score of 0 at Weeks 8 and 16 will be reported. The PSSD is a self-administered patient-reported outcome (PRO) instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.'}, {'measure': 'JNJ-77242113 and Placebo Group: Percentage of Participants Achieving >=4 Point Improvement From Baseline in PSSD Itch Score at Weeks 4 and 16', 'timeFrame': 'Baseline, Weeks 4 and 16', 'description': 'Percentage of participants achieving \\>=4 Point improvement from baseline in PSSD itch score at Weeks 4 and 16 will be reported. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.'}, {'measure': 'JNJ-77242113 and Deucravacitinib Group: : Percentage of Participants Achieving an IGA Score of 0 or 1 and >=2 Grade Improvement From Baseline at Weeks 16 and 24', 'timeFrame': 'Baseline, Weeks 16 and 24', 'description': "Percentage of participants who achieve an IGA score of 0 or 1 and \\>=2 grade improvement from baseline at Weeks 16 and 24 will be reported. The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4)."}, {'measure': 'JNJ-77242113 and Deucravacitinib Group: Percentage of Participants Achieving an IGA Score of 0 at Weeks 16 and 24', 'timeFrame': 'Weeks 16 and 24', 'description': "Percentage of participants who achieve an IGA score of 0 at Weeks 16 and 24 will be reported. The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4)."}, {'measure': 'JNJ-77242113 and Deucravacitinib Group: Percentage of Participants Achieving PASI 75 Response at Weeks 16 and 24', 'timeFrame': 'Baseline, Weeks 16 and 24', 'description': 'Percentage of participants achieving PASI 75 response (\\>=75% improvement in PASI from baseline) at Weeks 16 and 24 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.'}, {'measure': 'JNJ-77242113 and Deucravacitinib Group: Percentage of Participants Achieving PASI 90 Response at Weeks 16 and 24', 'timeFrame': 'Baseline, Weeks 16 and 24', 'description': 'Percentage of participants achieving PASI 90 response (\\>=90% improvement in PASI from baseline) at Weeks 16 and 24 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.'}, {'measure': 'JNJ-77242113 and Deucravacitinib Group: Percentage of Participants Achieving PASI 100 Response at Weeks 16 and 24', 'timeFrame': 'Weeks 16 and 24', 'description': 'Percentage of participants achieving PASI 100 response (\\>=100% improvement in PASI) at Weeks 16 and 24 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.'}, {'measure': 'JNJ-77242113 and Deucravacitinib Group: Percentage of Participants With PSSD Symptom Score of 0 at Week 16', 'timeFrame': 'Week 16', 'description': 'Percentage of participants achieving PSSD symptom score 0 at Week 16 will be reported. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.'}, {'measure': 'Number of Participants with Adverse Events (AEs)', 'timeFrame': 'Up to 165 weeks', 'description': 'An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.'}, {'measure': 'Number of Participants with Serious Adverse Events (SAEs)', 'timeFrame': 'Up to 165 weeks', 'description': 'SAEs are any AE which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product, or is medically important.'}, {'measure': 'Change From Baseline in Body Surface Area (BSA) at Week 16', 'timeFrame': 'Baseline and Week 16', 'description': 'Change from baseline in BSA at Week 16 will be reported. BSA is a commonly used measure of extent of skin disease. It is defined as the percentage of surface area of the body involved with the condition being assessed (that is, plaque psoriasis).'}, {'measure': 'Change from Baseline in PASI Score at Week 16', 'timeFrame': 'Baseline and Week 16', 'description': 'Change from baseline in PASI score at Week 16 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas are assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.'}, {'measure': 'Percent Improvement in PASI Score From Baseline at Week 16', 'timeFrame': 'Baseline and Week 16', 'description': 'Percent improvement in PASI score from Baseline at Week 16 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.'}, {'measure': "JNJ-77242113 and Placebo Group: Percentage of Participants Achieving a Static Physician's Global Assessment of Genitalia (sPGA-G) Score of 0 or 1 and >=2-grade Improvement From Baseline to Week 16", 'timeFrame': 'Baseline and Week 16', 'description': 'Percentage of participants achieving a sPGA-G Score of 0 or 1 and \\>=2-grade improvement from baseline to Week 16 will be reported. The sPGA-G is a 6-point scale to assess the severity of genital psoriasis at a given time point. The sPGA-G evaluates erythema, plaque elevation, and scale of genital psoriatic lesions. The severity of genital psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), and very severe (5).'}, {'measure': "JNJ-77242113 and Placebo Group: Percentage of Participants Achieving a Physician's Global Assessment of Hands and Feet (hf-PGA) Score of 0 or 1 and at Least a 2-grade Improvement From Baseline to Week 16", 'timeFrame': 'Baseline and Week 16', 'description': 'Percentage of participants achieving a hf-PGA score of 0 or 1 and at least a 2-grade improvement from baseline to Week 16 will be reported. The hf-PGA assesses the severity of hand and foot psoriasis using a 5-point scale to score the plaques on the hands and feet as: clear (0), almost clear (1), mild (2), moderate (3), and severe (4).'}, {'measure': 'JNJ-77242113 and Placebo Group: Percent Change From Baseline in Modified Nail Psoriasis Severity Index (mNAPSI) Score at Week 16', 'timeFrame': 'Baseline and Week 16', 'description': "Percent change from baseline in mNAPSI score at Week 16 will be reported. The mNAPSI is an index used for assessing and grading the severity of nail psoriasis. Each of the participant's 10 fingernails are evaluated for 7 features. The first 3 features are each scored from 0 to 3 in severity and are (1) onycholysis and oil-drop dyschromia, (2) pitting, and (3) nail plate crumbling. The next 4 features are scored 0 - absent or 1 - present and are (1) leukonychia, (2) splinter hemorrhages, (3) nail bed hyperkeratosis, and (4) red spots in the lunula. The score ranges from 0 to 13 per nail and 0 to 130 for all fingernails."}, {'measure': "JNJ-77242113 and Placebo Group: Percent of Participants Achieving Fingernail Physician's Global Assessment (f-PGA) Score of 0 or 1 at Week 16", 'timeFrame': 'Week 16', 'description': "Percent of participants achieving f-PGA score of 0 or 1 at Week 16 will be reported. The f-PGA is used to evaluate the current status of a participant's fingernail psoriasis on a scale of 0 to 4 (clear \\[0\\], minimal \\[1\\], mild \\[2\\], moderate \\[3\\], or severe \\[4\\])."}, {'measure': 'JNJ-77242113 and Placebo Group: Change From Baseline in PSSD Symptom Score at Week 16', 'timeFrame': 'Baseline and Week 16', 'description': 'Change from baseline in PSSD symptom score at Week 16 will be reported. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.'}, {'measure': 'JNJ-77242113 and Placebo Group: Change From Baseline in PSSD Sign Score at Week 16', 'timeFrame': 'Baseline and Week 16', 'description': 'Change from baseline in PSSD sign score at Week 16 will be reported. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.'}, {'measure': 'JNJ-77242113 and Placebo Group: Percentage of Participants With PSSD Sign Score of 0 at Week 16', 'timeFrame': 'Week 16', 'description': 'Percentage of participants with PSSD sign score of 0 at Week 16 will be reported. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.'}, {'measure': 'JNJ-77242113 and Placebo Group: Percentage of Participants Achieving Genital Psoriasis Sexual Frequency Questionnaire (GenPs-SFQ) Item 2 Score of 0 or 1 at Week 16', 'timeFrame': 'Week 16', 'description': 'Percentage of participants achieving GenPs-SFQ Item 2 score of 0 or 1 at Week 16 will be reported. The GenPs-SFQ is a 2-item participant-reported instrument used to assess the impact of genital psoriasis on the frequency of sexual activity in the last 7 days. Item 1 assesses overall frequency of sexual activity in the last 7 days (none/zero, once, or 2 or more times), and item 2 assesses how frequently genital psoriasis symptoms have limited the frequency of sexual activity in the last 7 days (never \\[0\\], rarely \\[1\\], sometimes \\[2\\], often \\[3\\], or always \\[4\\]).'}, {'measure': 'JNJ-77242113 and Placebo Group: Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) Total Score of 0 or 1 at Week 16', 'timeFrame': 'Week 16', 'description': "Percentage of participants achieving DLQI total score of 0 or 1 at Week 16 will be reported. The DLQI is a dermatology specific health-related quality of life (HRQoL) instrument designed to assess the impact of the disease on a participant's HRQoL. It is a 10-item questionnaire that assesses HRQoL over the past week and in addition to evaluating overall HRQoL, can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL."}, {'measure': 'JNJ-77242113 and Placebo Group: Change From Baseline in Total DLQI Score at Week 16', 'timeFrame': 'Baseline and Week 16', 'description': "Change from baseline in total DLQI score at Week 16 will be reported. The DLQI is a dermatology specific HRQoL instrument designed to assess the impact of the disease on a participant's HRQoL. It is a 10-item questionnaire that assesses HRQoL over the past week and in addition to evaluating overall HRQoL, can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL."}, {'measure': 'JNJ-77242113 and Placebo Group: Change from Baseline in Domain Scores of the Patient-reported Outcomes Measurement Information System-29 (PROMIS-29) Score at Week 16', 'timeFrame': 'Baseline and Week 16', 'description': 'Change from baseline in domain scores of the PROMIS-29 score at Week 16 will be reported. The PROMIS-29 is a 29-item generic HRQoL survey, assessing each of the 7 PROMIS domains (depression, anxiety, physical function, pain interference, fatigue, sleep disturbance, and ability to participate in social roles and activities) with 4 questions for each domain. The questions are ranked on a 5-point Likert scale. There is also a numerical rating scale that ranges from 0 (No pain) to 10 (Worst pain imaginable) for pain intensity. The raw domain scores are converted to standardized T-scores with a mean of 50 and a standard deviation of 10. Higher scores on anxiety, depression, fatigue, sleep disturbance, and pain interference indicate more severe symptoms. Higher scores on physical function and social participation indicate better health outcomes.'}, {'measure': 'JNJ-77242113 and Deucravacitinib Group: Percentage of Participants Achieving DLQI Score of 0 or 1 at Weeks 16 and 24', 'timeFrame': 'Weeks 16 and 24', 'description': "Percentage of participants achieving DLQI score of 0 or 1 at Weeks 16 and 24 will be reported. The DLQI is a dermatology specific HRQoL instrument designed to assess the impact of the disease on a participant's HRQoL. It is a 10-item questionnaire that assesses HRQoL over the past week and in addition to evaluating overall HRQoL, can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL."}, {'measure': 'JNJ-77242113 and Deucravacitinib Group: Percentage of Participants Achieving PSSD Symptom Score of 0 at Week 24', 'timeFrame': 'Week 24', 'description': 'Percentage of participants achieving PSSD symptom score of 0 at Week 24 will be reported. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.'}, {'measure': 'Percentage of Participants Who Achieve PASI 75 Response After Week 24 Among PASI 75 Non-responders to Deucravacitinib at Week 24', 'timeFrame': 'Baseline and from Week 24 through Week 156', 'description': 'Percentage of participants who achieve PASI 75 response (\\>=75% improvement in PASI) after Week 24 among PASI 75 Non-responders to deucravacitinib at Week 24 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.'}, {'measure': 'Percentage of Participants Who Achieve PASI 90 Response After Week 24 Among PASI 90 Non-responders to Deucravacitinib at Week 24', 'timeFrame': 'Baseline and from Week 24 through Week 156', 'description': 'Percentage of participants who achieve PASI 90 response (\\>=90% improvement in PASI) after Week 24 among PASI 90 non-responders to deucravacitinib at Week 24 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.'}, {'measure': 'Percentage of Participants Achieving IGA Score of 0 or 1 after Week 24, Among Participants with IGA score >=2 at Week 24 in the Deucravacitinib Group', 'timeFrame': 'From Week 24 through Week 156', 'description': "Percentage of participants achieving IGA score of 0 or 1 after Week 24, among participants with IGA score \\>=2 at Week 24 in the deucravacitinib group will be reported. The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4)."}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Plaque Psoriasis']}, 'referencesModule': {'references': [{'pmid': '40976249', 'type': 'DERIVED', 'citation': 'Gold LS, Armstrong AW, Bissonnette R, Magnolo N, Vender RB, Sebastian M, Galimberti ML, Tsianakas A, Arnone M, Wallace P, Simon M, Riera-Monroig J, Gerdes S, Waibel J, Gonzalez-Cantero A, Schwarz B, Tada Y, Cecchini M, Ehst B, Kircik L, Kephart L, Reyes-Servin O, Edem BE, Campbell JH, Shen YK, Cresswell K, Li S, DeKlotz CMC, Nunes F, Papp KA. Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phase 3, randomised, placebo-controlled and active-comparator-controlled trials. Lancet. 2025 Sep 27;406(10510):1363-1374. doi: 10.1016/S0140-6736(25)01576-4. Epub 2025 Sep 18.'}]}, 'descriptionModule': {'briefSummary': 'The purpose of the study is to evaluate how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), for at least 26 weeks prior to the first administration of study intervention\n* Total body surface area (BSA) greater than or equal to (\\>=)10 percent (%) at screening and baseline\n* Total psoriasis area and severity index (PASI) \\>=12 at screening and baseline\n* Total investigator global assessment (IGA) \\>=3 at screening and baseline\n* Candidate for phototherapy or systemic treatment for plaque psoriasis\n\nExclusion Criteria:\n\n* Nonplaque form of psoriasis (for example, erythrodermic, guttate, or pustular)\n* Current drug-induced psoriasis (for example, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)\n* A current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, liver, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances\n* Known allergies, hypersensitivity, or intolerance to JNJ-77242113, deucravacitinib or to any of the excipients or components of the study intervention\n* Major surgical procedure, (for example, requiring general anesthesia) within 8 weeks before screening, or will not have fully recovered from surgical procedure, or has a surgical procedure planned during the time the participant is expected to participate in the study'}, 'identificationModule': {'nctId': 'NCT06220604', 'briefTitle': 'A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)', 'organization': {'class': 'INDUSTRY', 'fullName': 'Janssen Research & Development, LLC'}, 'officialTitle': 'A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis', 'orgStudyIdInfo': {'id': '77242113PSO3004'}, 'secondaryIdInfos': [{'id': '77242113PSO3004', 'type': 'OTHER', 'domain': 'Janssen Research & Development, LLC'}, {'id': '2023-507039-39-00', 'type': 'REGISTRY', 'domain': 'EUCT number'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'JNJ-77242113', 'description': 'Participants will receive JNJ-77242113 from Week 0 through Week 156 and deucravacitinib matching placebo from Week 0 through Week 24.', 'interventionNames': ['Drug: JNJ-77242113', 'Drug: Deucravacitinib Matching Placebo']}, {'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo', 'description': 'Participants will receive matching placebo for JNJ-77242113 from Week 0 through Week 16, matching placebo for deucravacitinib from Week 0 through Week 24 and JNJ-77242113 from Week 16 through Week 156.', 'interventionNames': ['Drug: JNJ-77242113', 'Drug: JNJ-77242113 Matching Placebo', 'Drug: Deucravacitinib Matching Placebo']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Deucravacitinib', 'description': 'Participants will receive deucravacitinib from Week 0 through Week 24 and matching placebo for JNJ-77242113 from Week 0 through Week 24 and JNJ-77242113 from Week 24 through Week 156.', 'interventionNames': ['Drug: JNJ-77242113', 'Drug: JNJ-77242113 Matching Placebo', 'Drug: Deucravacitinib']}], 'interventions': [{'name': 'JNJ-77242113', 'type': 'DRUG', 'description': 'JNJ-77242113 will be administered orally.', 'armGroupLabels': ['Deucravacitinib', 'JNJ-77242113', 'Placebo']}, {'name': 'JNJ-77242113 Matching Placebo', 'type': 'DRUG', 'description': 'JNJ-77242113 matching placebo will be administered orally.', 'armGroupLabels': ['Deucravacitinib', 'Placebo']}, {'name': 'Deucravacitinib', 'type': 'DRUG', 'description': 'Deucravacitinib will be administered orally.', 'armGroupLabels': ['Deucravacitinib']}, {'name': 'Deucravacitinib Matching Placebo', 'type': 'DRUG', 'description': 'Deucravacitinib matching placebo will be administered orally.', 'armGroupLabels': ['JNJ-77242113', 'Placebo']}]}, 'contactsLocationsModule': {'locations': [{'zip': '85032', 'city': 'Phoenix', 'state': 'Arizona', 'country': 'United States', 'facility': 'Alliance Dermatology and MOHS Center P C', 'geoPoint': {'lat': 33.44838, 'lon': -112.07404}}, {'zip': '92024', 'city': 'Encinitas', 'state': 'California', 'country': 'United States', 'facility': 'California Dermatology & Clinical Research Institute', 'geoPoint': {'lat': 33.03699, 'lon': -117.29198}}, {'zip': '91436', 'city': 'Encino', 'state': 'California', 'country': 'United States', 'facility': 'T Joseph Raoof Md Inc', 'geoPoint': {'lat': 34.15917, 'lon': -118.50119}}, {'zip': '93701', 'city': 'Fresno', 'state': 'California', 'country': 'United States', 'facility': 'UCSF Fresno', 'geoPoint': {'lat': 36.74773, 'lon': -119.77237}}, {'zip': '90024', 'city': 'Los Angeles', 'state': 'California', 'country': 'United States', 'facility': 'University of California Los Angeles - Division of Dermatology', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '90056', 'city': 'Los Angeles', 'state': 'California', 'country': 'United States', 'facility': 'Wallace Medical Group, Inc', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '92056', 'city': 'Oceanside', 'state': 'California', 'country': 'United States', 'facility': 'Dermatologist Medical Group of North County, Inc.', 'geoPoint': {'lat': 33.19587, 'lon': -117.37948}}, {'zip': '33133', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'Miami Dermatology And Laser Institute', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '33155', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'Bioclinical Research Alliance Inc.', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '33613', 'city': 'Tampa', 'state': 'Florida', 'country': 'United States', 'facility': 'Forcare Clinical Research Inc', 'geoPoint': {'lat': 27.94752, 'lon': -82.45843}}, {'zip': '30135', 'city': 'Douglasville', 'state': 'Georgia', 'country': 'United States', 'facility': 'Southeast Dermatology Specialists', 'geoPoint': {'lat': 33.7515, 'lon': -84.74771}}, {'zip': '60008', 'city': 'Rolling Meadows', 'state': 'Illinois', 'country': 'United States', 'facility': 'Arlington Dermatology', 'geoPoint': {'lat': 42.08419, 'lon': -88.01313}}, {'zip': '40217', 'city': 'Louisville', 'state': 'Kentucky', 'country': 'United States', 'facility': 'Skin Sciences, PLLC', 'geoPoint': {'lat': 38.25424, 'lon': -85.75941}}, {'zip': '42301', 'city': 'Owensboro', 'state': 'Kentucky', 'country': 'United States', 'facility': 'Qualmedica Research', 'geoPoint': {'lat': 37.77422, 'lon': -87.11333}}, {'zip': '20850', 'city': 'Rockville', 'state': 'Maryland', 'country': 'United States', 'facility': 'DermAssociates, PC', 'geoPoint': {'lat': 39.084, 'lon': -77.15276}}, {'zip': '02135', 'city': 'Brighton', 'state': 'Massachusetts', 'country': 'United States', 'facility': 'Metro Boston Clinical Partners', 'geoPoint': {'lat': 42.3501, 'lon': -71.15644}}, {'zip': '01844', 'city': 'Methuen', 'state': 'Massachusetts', 'country': 'United States', 'facility': 'ActivMed Practices and Research', 'geoPoint': {'lat': 42.7262, 'lon': -71.19089}}, {'zip': '48109', 'city': 'Ann Arbor', 'state': 'Michigan', 'country': 'United States', 'facility': 'University of Michigan', 'geoPoint': {'lat': 42.27756, 'lon': -83.74088}}, {'zip': '48706', 'city': 'Bay City', 'state': 'Michigan', 'country': 'United States', 'facility': 'Great Lakes Research Group', 'geoPoint': {'lat': 43.59447, 'lon': -83.88886}}, {'zip': '49316', 'city': 'Caledonia', 'state': 'Michigan', 'country': 'United States', 'facility': 'The Derm Institute of West Michigan', 'geoPoint': {'lat': 42.7892, 'lon': -85.51669}}, {'zip': '48187', 'city': 'Canton', 'state': 'Michigan', 'country': 'United States', 'facility': 'Hamzavi Dermatology', 'geoPoint': {'lat': 42.30865, 'lon': -83.48216}}, {'zip': '48084', 'city': 'Troy', 'state': 'Michigan', 'country': 'United States', 'facility': 'Somerset Skin Centre', 'geoPoint': {'lat': 42.60559, 'lon': -83.14993}}, {'zip': '63501', 'city': 'Kirksville', 'state': 'Missouri', 'country': 'United States', 'facility': 'Cleaver Dermatology', 'geoPoint': {'lat': 40.19475, 'lon': -92.58325}}, {'zip': '43209', 'city': 'Bexley', 'state': 'Ohio', 'country': 'United States', 'facility': 'Bexley dermatology research', 'geoPoint': {'lat': 39.96895, 'lon': -82.93768}}, {'zip': '74137', 'city': 'Tulsa', 'state': 'Oklahoma', 'country': 'United States', 'facility': 'Essential Medical Research', 'geoPoint': {'lat': 36.15398, 'lon': -95.99277}}, {'zip': '97210-2996', 'city': 'Portland', 'state': 'Oregon', 'country': 'United States', 'facility': 'Oregon Dermatology & Research Center', 'geoPoint': {'lat': 45.52345, 'lon': -122.67621}}, {'zip': '19103', 'city': 'Philadelphia', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Paddington Testing Co, Inc.', 'geoPoint': {'lat': 39.95238, 'lon': -75.16362}}, {'zip': '29407', 'city': 'Charleston', 'state': 'South Carolina', 'country': 'United States', 'facility': 'Clinical Research Center of the Carolinas LLC', 'geoPoint': {'lat': 32.77632, 'lon': -79.93275}}, {'zip': '29615', 'city': 'Greenville', 'state': 'South Carolina', 'country': 'United States', 'facility': 'Palmetto Clinical Trial Services, LLC', 'geoPoint': {'lat': 34.85262, 'lon': -82.39401}}, {'zip': '76011', 'city': 'Arlington', 'state': 'Texas', 'country': 'United States', 'facility': 'Arlington Research Center, Inc.', 'geoPoint': {'lat': 32.73569, 'lon': -97.10807}}, {'zip': '75390', 'city': 'Dallas', 'state': 'Texas', 'country': 'United States', 'facility': 'UT Southwestern Medical Center', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '78229', 'city': 'San Antonio', 'state': 'Texas', 'country': 'United States', 'facility': 'Dermatology Clinical Research Center of San Antonio', 'geoPoint': {'lat': 29.42412, 'lon': -98.49363}}, {'zip': '77598', 'city': 'Webster', 'state': 'Texas', 'country': 'United States', 'facility': 'Center for Clinical Studies', 'geoPoint': {'lat': 29.53773, 'lon': -95.11826}}, {'zip': '84010', 'city': 'Bountiful', 'state': 'Utah', 'country': 'United States', 'facility': 'Cope Family Medicine - Ogden Clinic', 'geoPoint': {'lat': 40.88939, 'lon': -111.88077}}, {'zip': '84663', 'city': 'Springville', 'state': 'Utah', 'country': 'United States', 'facility': 'Springville Dermatology CCT Research', 'geoPoint': {'lat': 40.16523, 'lon': -111.61075}}, {'zip': '84120', 'city': 'West Valley City', 'state': 'Utah', 'country': 'United States', 'facility': 'Kalo Clinical Research', 'geoPoint': {'lat': 40.69161, 'lon': -112.00105}}, {'zip': '23502', 'city': 'Norfolk', 'state': 'Virginia', 'country': 'United States', 'facility': 'Virginia Dermatology Skin Cancer Center Pllc', 'geoPoint': {'lat': 36.84681, 'lon': -76.28522}}, {'zip': '4217', 'city': 'Benowa', 'country': 'Australia', 'facility': 'The Skin Centre', 'geoPoint': {'lat': -28.0077, 'lon': 153.38583}}, {'zip': '3168', 'city': 'Clayton', 'country': 'Australia', 'facility': 'Monash Medical Centre', 'geoPoint': {'lat': -37.91667, 'lon': 145.11667}}, {'zip': '2217', 'city': 'Kogarah', 'country': 'Australia', 'facility': 'Premier Specialists', 'geoPoint': {'lat': -33.9681, 'lon': 151.13564}}, {'zip': '3004', 'city': 'Melbourne', 'country': 'Australia', 'facility': 'The Alfred Hospital', 'geoPoint': {'lat': -37.814, 'lon': 144.96332}}, {'zip': '3132', 'city': 'Mitcham', 'country': 'Australia', 'facility': 'ISHI dermatology', 'geoPoint': {'lat': -37.81667, 'lon': 145.2}}, {'zip': '3050', 'city': 'Parkville', 'country': 'Australia', 'facility': 'Royal Melbourne Hospital', 'geoPoint': {'lat': -37.78333, 'lon': 144.95}}, {'zip': '18618-687', 'city': 'Botucatu', 'country': 'Brazil', 'facility': 'UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu', 'geoPoint': {'lat': -22.88583, 'lon': -48.445}}, {'zip': '72.145-450', 'city': 'Brasília', 'country': 'Brazil', 'facility': 'Chronos Clinica Medica LTDA Chronos Pesquisa Clinica', 'geoPoint': {'lat': -15.77972, 'lon': -47.92972}}, {'zip': '14048 900', 'city': 'Ribeirão Preto', 'country': 'Brazil', 'facility': 'Hospital Das Clinicas Da Faculdade De Medicina De RPUSP HCRP', 'geoPoint': {'lat': -21.1775, 'lon': -47.81028}}, {'zip': '09060 870', 'city': 'Santo André', 'country': 'Brazil', 'facility': 'Fundacao do ABC Centro Universitario FMABC', 'geoPoint': {'lat': -23.66389, 'lon': -46.53833}}, {'zip': '15090 000', 'city': 'São José do Rio Preto', 'country': 'Brazil', 'facility': 'Fundacao Faculdade Regional De Medicina S Jose Rio Preto Hospital De Base', 'geoPoint': {'lat': -20.81972, 'lon': -49.37944}}, {'zip': '05403 900', 'city': 'São Paulo', 'country': 'Brazil', 'facility': 'Hospital Das Clinicas Da Faculdade De Medicina Da USP', 'geoPoint': {'lat': -23.5475, 'lon': -46.63611}}, {'zip': 'V3R 6A7', 'city': 'Surrey', 'state': 'British Columbia', 'country': 'Canada', 'facility': 'Dr. Chih ho Hong Medical', 'geoPoint': {'lat': 49.10635, 'lon': -122.82509}}, {'zip': 'R3M 3Z4', 'city': 'Winnipeg', 'state': 'Manitoba', 'country': 'Canada', 'facility': 'Wiseman Dermatology Research Inc.', 'geoPoint': {'lat': 49.8844, 'lon': -97.14704}}, {'zip': 'N6A 5R9', 'city': 'London', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Lovegrove Dermatology', 'geoPoint': {'lat': 42.98339, 'lon': -81.23304}}, {'zip': 'L3P 1X2', 'city': 'Markham', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Lynderm Research Inc.', 'geoPoint': {'lat': 43.86682, 'lon': -79.2663}}, {'zip': 'L4Y 4C5', 'city': 'Mississauga', 'state': 'Ontario', 'country': 'Canada', 'facility': 'DermEdge Research', 'geoPoint': {'lat': 43.5789, 'lon': -79.6583}}, {'zip': 'K9J 5K2', 'city': 'Peterborough', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Skin Centre for Dermatology', 'geoPoint': {'lat': 44.30012, 'lon': -78.31623}}, {'zip': 'M2N 3A6', 'city': 'Toronto', 'state': 'Ontario', 'country': 'Canada', 'facility': 'North York Research Inc', 'geoPoint': {'lat': 43.70643, 'lon': -79.39864}}, {'zip': 'M3H 5Y8', 'city': 'Toronto', 'state': 'Ontario', 'country': 'Canada', 'facility': 'Toronto Research Centre', 'geoPoint': {'lat': 43.70643, 'lon': -79.39864}}, {'zip': 'N8T 1E6', 'city': 'Windsor', 'state': 'Ontario', 'country': 'Canada', 'facility': 'XLR8 Medical Research', 'geoPoint': {'lat': 42.30008, 'lon': -83.01654}}, {'zip': 'H2X 2V1', 'city': 'Montreal', 'state': 'Quebec', 'country': 'Canada', 'facility': 'Innovaderm Research Inc.', 'geoPoint': {'lat': 45.50884, 'lon': -73.58781}}, {'zip': 'G1V 4X7', 'city': 'Québec', 'state': 'Quebec', 'country': 'Canada', 'facility': 'Centre De Recherche Dermatologique Du Quebec Metropolitain', 'geoPoint': {'lat': 46.81228, 'lon': -71.21454}}, {'zip': '86150', 'city': 'Augsburg', 'country': 'Germany', 'facility': 'Hautarztpraxis Dr. Mihaescu', 'geoPoint': {'lat': 48.37154, 'lon': 10.89851}}, {'zip': '48455', 'city': 'Bad Bentheim', 'country': 'Germany', 'facility': 'Fachklinik Bad Bentheim', 'geoPoint': {'lat': 52.30066, 'lon': 7.15763}}, {'zip': '13627', 'city': 'Berlin', 'country': 'Germany', 'facility': 'CRS Clinical Research Services Berlin GmbH', 'geoPoint': {'lat': 52.52437, 'lon': 13.41053}}, {'zip': '44793', 'city': 'Bochum', 'country': 'Germany', 'facility': 'Niesmann & Othlinghaus GbR', 'geoPoint': {'lat': 51.48165, 'lon': 7.21648}}, {'zip': '64283', 'city': 'Darmstadt', 'country': 'Germany', 'facility': 'Klinikum Darmstadt GmbH - Hautklinik', 'geoPoint': {'lat': 49.87167, 'lon': 8.65027}}, {'zip': '01307', 'city': 'Dresden', 'country': 'Germany', 'facility': 'Medizinische Fakultaet Carl Gustav Carus Technische Universitaet Dresden', 'geoPoint': {'lat': 51.05089, 'lon': 13.73832}}, {'zip': '48249', 'city': 'Dülmen', 'country': 'Germany', 'facility': 'Hautzentrum Dulmen', 'geoPoint': {'lat': 51.83149, 'lon': 7.28075}}, {'zip': '40212', 'city': 'Düsseldorf', 'country': 'Germany', 'facility': 'Privatpraxis Dr. Hilton & Partner', 'geoPoint': {'lat': 51.22172, 'lon': 6.77616}}, {'zip': '88045', 'city': 'Friedrichshafen', 'country': 'Germany', 'facility': 'Derma-Study-Center Friedrichshafen GmbH', 'geoPoint': {'lat': 47.65689, 'lon': 9.47554}}, {'zip': '20095', 'city': 'Hamburg', 'country': 'Germany', 'facility': 'Eurofins bioskin GmbH', 'geoPoint': {'lat': 53.55073, 'lon': 9.99302}}, {'zip': '69120', 'city': 'Heidelberg', 'country': 'Germany', 'facility': 'Universitaetsklinikum Heidelberg', 'geoPoint': {'lat': 49.40768, 'lon': 8.69079}}, {'zip': '15831', 'city': 'Mahlow', 'country': 'Germany', 'facility': 'Hautarztpraxis', 'geoPoint': {'lat': 52.36017, 'lon': 13.40954}}, {'zip': '55131', 'city': 'Mainz', 'country': 'Germany', 'facility': 'Universitatsmedizin der Johannes Gutenberg Universitat Mainz', 'geoPoint': {'lat': 49.98185, 'lon': 8.28008}}, {'zip': '66663', 'city': 'Merzig', 'country': 'Germany', 'facility': 'Hautmedizin Saar', 'geoPoint': {'lat': 49.44331, 'lon': 6.63874}}, {'zip': '48149', 'city': 'Münster', 'country': 'Germany', 'facility': 'Universitaetsklinikum Muenster', 'geoPoint': {'lat': 51.96236, 'lon': 7.62571}}, {'zip': '26133', 'city': 'Oldenburg', 'country': 'Germany', 'facility': 'Klinikum Oldenburg', 'geoPoint': {'lat': 53.14039, 'lon': 8.21479}}, {'zip': '58453', 'city': 'Witten', 'country': 'Germany', 'facility': 'Hautarztpraxis', 'geoPoint': {'lat': 51.44362, 'lon': 7.35258}}, {'zip': '42287', 'city': 'Wuppertal', 'country': 'Germany', 'facility': 'CentroDerm GmbH', 'geoPoint': {'lat': 51.25627, 'lon': 7.14816}}, {'zip': '1152', 'city': 'Budapest', 'country': 'Hungary', 'facility': 'Uno Medical Trials Ltd.', 'geoPoint': {'lat': 47.49835, 'lon': 19.04045}}, {'zip': '3200', 'city': 'Gyöngyös', 'country': 'Hungary', 'facility': 'Bugat Pal Korhaz', 'geoPoint': {'lat': 47.78257, 'lon': 19.928}}, {'zip': '5700', 'city': 'Gyula', 'country': 'Hungary', 'facility': 'Synexus Magyarorszag Kft', 'geoPoint': {'lat': 46.65, 'lon': 21.28333}}, {'zip': '6000', 'city': 'Kecskemét', 'country': 'Hungary', 'facility': 'Bacs Kiskun Varmegyei Oktatokorhaz', 'geoPoint': {'lat': 46.90618, 'lon': 19.69128}}, {'zip': 'H-8900', 'city': 'Zalaegerszeg', 'country': 'Hungary', 'facility': 'Synexus Magyarorszag Kft', 'geoPoint': {'lat': 46.83695, 'lon': 16.84401}}, {'zip': '15 797', 'city': 'Bialystok', 'country': 'Poland', 'facility': 'Renew Clinic', 'geoPoint': {'lat': 53.13333, 'lon': 23.16433}}, {'zip': '40 568', 'city': 'Katowice', 'country': 'Poland', 'facility': 'Care Clinic', 'geoPoint': {'lat': 50.2597, 'lon': 19.02173}}, {'zip': '40 611', 'city': 'Katowice', 'country': 'Poland', 'facility': 'Centrum Medyczne Angelius Provita', 'geoPoint': {'lat': 50.2597, 'lon': 19.02173}}, {'zip': '25-316', 'city': 'Kielce', 'country': 'Poland', 'facility': 'Prywatny Gabinet Dermatologiczny Elzbieta Klujszo', 'geoPoint': {'lat': 50.87033, 'lon': 20.62752}}, {'zip': '30-002', 'city': 'Krakow', 'country': 'Poland', 'facility': 'SGD s.c.', 'geoPoint': {'lat': 50.06143, 'lon': 19.93658}}, {'zip': '30-303', 'city': 'Krakow', 'country': 'Poland', 'facility': 'Krakowskie Centrum Badan Klinicznych', 'geoPoint': {'lat': 50.06143, 'lon': 19.93658}}, {'zip': '30-348', 'city': 'Krakow', 'country': 'Poland', 'facility': 'Jagiellonskie Centrum Innowacji', 'geoPoint': {'lat': 50.06143, 'lon': 19.93658}}, {'zip': '31 559', 'city': 'Krakow', 'country': 'Poland', 'facility': 'Diamond Clinic', 'geoPoint': {'lat': 50.06143, 'lon': 19.93658}}, {'zip': '10-117', 'city': 'Olsztyn', 'country': 'Poland', 'facility': 'Etyka Osrodek Badan Klinicznych', 'geoPoint': {'lat': 53.78376, 'lon': 20.49272}}, {'zip': '02 661', 'city': 'Warsaw', 'country': 'Poland', 'facility': 'Carpe Diem Centrum Medycyny Estetycznej', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'zip': '02 672', 'city': 'Warsaw', 'country': 'Poland', 'facility': 'Synexus Polska Sp z o o Oddzial w Warszawie', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'zip': '02-962', 'city': 'Warsaw', 'country': 'Poland', 'facility': 'Royalderm Agnieszka Nawrocka', 'geoPoint': {'lat': 52.22977, 'lon': 21.01178}}, {'zip': '51 685', 'city': 'Wroclaw', 'country': 'Poland', 'facility': 'WroMedica I Bielicka A Strzalkowska s c', 'geoPoint': {'lat': 51.10286, 'lon': 17.03006}}, {'zip': '400105', 'city': 'Cluj-Napoca', 'country': 'Romania', 'facility': 'Cabinet Medical Dermato-Venerologie', 'geoPoint': {'lat': 46.76667, 'lon': 23.6}}, {'zip': '200541', 'city': 'Craiova', 'country': 'Romania', 'facility': 'Centrul Medical Vitaplus', 'geoPoint': {'lat': 44.31667, 'lon': 23.8}}, {'zip': '200642', 'city': 'Craiova', 'country': 'Romania', 'facility': 'Spitalul Clinic Judetean de Urgenta', 'geoPoint': {'lat': 44.31667, 'lon': 23.8}}, {'zip': '700381', 'city': 'Iași', 'country': 'Romania', 'facility': 'Sc Iasiprest Srl', 'geoPoint': {'lat': 47.16667, 'lon': 27.6}}, {'zip': '410167', 'city': 'Oradea', 'country': 'Romania', 'facility': 'Spitalul Clinic Judetean de Urgenta Bihor', 'geoPoint': {'lat': 47.0458, 'lon': 21.91833}}, {'zip': '540342', 'city': 'Târgu Mureş', 'country': 'Romania', 'facility': 'Spitalul Clinic Judetean Mures', 'geoPoint': {'lat': 46.54245, 'lon': 24.55747}}, {'zip': '300757', 'city': 'Timișoara', 'country': 'Romania', 'facility': 'New Derm Clinic', 'geoPoint': {'lat': 45.75372, 'lon': 21.22571}}, {'zip': '15355', 'city': 'Ansan-si', 'country': 'South Korea', 'facility': 'Korea University Ansan Hospital', 'geoPoint': {'lat': 37.32361, 'lon': 126.82194}}, {'zip': '14068', 'city': 'Anyang-si', 'country': 'South Korea', 'facility': 'Hallym University Sacred Heart Hospital', 'geoPoint': {'lat': 37.3925, 'lon': 126.92694}}, {'zip': '14647', 'city': 'Bucheon-si', 'country': 'South Korea', 'facility': 'The Catholic University of Korea Bucheon St Mary s Hospital', 'geoPoint': {'lat': 37.49889, 'lon': 126.78306}}, {'zip': '61453', 'city': 'Gwangju', 'country': 'South Korea', 'facility': 'Chosun university hospital', 'geoPoint': {'lat': 35.15472, 'lon': 126.91556}}, {'zip': '13496', 'city': 'Seongnam', 'country': 'South Korea', 'facility': 'CHA Bundang Medical Center, CHA University', 'geoPoint': {'lat': 35.54127, 'lon': 127.39683}}, {'zip': '05505', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Asan Medical Center', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '8308', 'city': 'Seoul', 'country': 'South Korea', 'facility': 'Korea University Guro Hospital', 'geoPoint': {'lat': 37.566, 'lon': 126.9784}}, {'zip': '28922', 'city': 'Alcorcón', 'country': 'Spain', 'facility': 'Hosp. Univ. Fundacion Alcorcon', 'geoPoint': {'lat': 40.34582, 'lon': -3.82487}}, {'zip': '08916', 'city': 'Badalona', 'country': 'Spain', 'facility': 'Hosp. Univ. Germans Trias I Pujol', 'geoPoint': {'lat': 41.45004, 'lon': 2.24741}}, {'zip': '08036', 'city': 'Barcelona', 'country': 'Spain', 'facility': 'Hosp Clinic de Barcelona', 'geoPoint': {'lat': 41.38879, 'lon': 2.15899}}, {'zip': '46940', 'city': 'Manises', 'country': 'Spain', 'facility': 'Hosp. de Manises', 'geoPoint': {'lat': 39.49139, 'lon': -0.46349}}, {'zip': '37007', 'city': 'Salamanca', 'country': 'Spain', 'facility': 'Hosp Clinico Univ de Salamanca', 'geoPoint': {'lat': 40.96882, 'lon': -5.66388}}, {'zip': '15702', 'city': 'Santiago de Compostela', 'country': 'Spain', 'facility': 'Clinica Gaias', 'geoPoint': {'lat': 42.88052, 'lon': -8.54569}}, {'zip': '15706', 'city': 'Santiago de Compostela', 'country': 'Spain', 'facility': 'Hosp. Clinico Univ. de Santiago', 'geoPoint': {'lat': 42.88052, 'lon': -8.54569}}, {'zip': '41009', 'city': 'Seville', 'country': 'Spain', 'facility': 'Hosp. Virgen Macarena', 'geoPoint': {'lat': 37.38283, 'lon': -5.97317}}, {'zip': '41014', 'city': 'Seville', 'country': 'Spain', 'facility': 'Hosp. Ntra. Sra. de Valme', 'geoPoint': {'lat': 37.38283, 'lon': -5.97317}}, {'zip': '03570', 'city': 'Villajoyosa', 'country': 'Spain', 'facility': 'Hosp. de La Marina Baixa', 'geoPoint': {'lat': 38.50754, 'lon': -0.23346}}, {'zip': '50009', 'city': 'Zaragoza', 'country': 'Spain', 'facility': 'Hosp. Clinico Univ. Lozano Blesa', 'geoPoint': {'lat': 41.65606, 'lon': -0.87734}}, {'zip': '80756', 'city': 'Kaohsiung City', 'country': 'Taiwan', 'facility': 'Kaohsiung Medical University Chung Ho Memorial Hospital', 'geoPoint': {'lat': 22.61626, 'lon': 120.31333}}, {'zip': '81362', 'city': 'Kaohsiung City', 'country': 'Taiwan', 'facility': 'Kaohsiung Veterans General Hospital', 'geoPoint': {'lat': 22.61626, 'lon': 120.31333}}, {'zip': '40201', 'city': 'Taichung', 'country': 'Taiwan', 'facility': 'Chung Shan Medical University Hospital', 'geoPoint': {'lat': 24.1469, 'lon': 120.6839}}, {'zip': '40705', 'city': 'Taichung', 'country': 'Taiwan', 'facility': 'Taichung Veterans General Hospital', 'geoPoint': {'lat': 24.1469, 'lon': 120.6839}}, {'zip': '710', 'city': 'Tainan', 'country': 'Taiwan', 'facility': 'National Cheng Kung University Hospital', 'geoPoint': {'lat': 22.99083, 'lon': 120.21333}}, {'zip': '110', 'city': 'Taipei', 'country': 'Taiwan', 'facility': 'Taipei Medical University', 'geoPoint': {'lat': 25.05306, 'lon': 121.52639}}, {'zip': '116', 'city': 'Taipei', 'country': 'Taiwan', 'facility': 'Taipei Municipal Wanfang Hospital', 'geoPoint': {'lat': 25.05306, 'lon': 121.52639}}], 'overallOfficials': [{'name': 'Janssen Research & Development, LLC Clinicaltrial', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Janssen Research & Development, LLC'}]}, 'ipdSharingStatementModule': {'url': 'https://www.janssen.com/clinical-trials/transparency', 'ipdSharing': 'YES', 'description': 'The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \\& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Janssen Research & Development, LLC', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}